ReviewCureus2024
Recent Advances in Image-Guided Tissue Sampling.
Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mixed reality navigation system for ultrasound-guided and fusion biopsies using markerless instrument tracking.Scientific reports · 2026Article
- Ultra-low-field MRI: a David versus Goliath challenge in modern imaging.La Radiologia medica · 2025Review
- Building a Therapeutic Bridge Between Dogs and Humans: A Review of Potential Cross-Species Osteosarcoma Biomarkers.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in image-guided tissue sampling have enhanced diagnostic medicine, particularly in oncology. Traditional techniques, such as computed tomography (CT)-, ultrasound (US)-, and magnetic resonance imaging (MRI)-guided biopsies, remain the cornerstone of diagnostic interventions, each offering unique advantages based on tissue characteristics. CT-guided biopsies excel in deeper complex lesions, while US-guided biopsies provide real-time imaging ideal for superficial tissues. MRI-guided biopsies are invaluable for soft tissue evaluations. The emergence of fusion imaging, which combines modalities such as positron emission tomography (PET)/CT or MRI/US, has demonstrated enhanced diagnostic accuracy. Despite these advantages, image co-registration and cost are the main drawbacks. Emerging techniques such as molecular breast imaging (MBI) and shear wave elastography (SWE) have been evaluated, particularly for breast cancer; however, research suggests that US is likely to remain the most effective modality due to both its cost and ease of use. Innovations in biopsy navigation, including augmented reality, "hot needles," and robotic assistance, demonstrate promise in closing the gap between operator dependency and procedural consistency; however, further research is required. While liquid biopsies show promise in non-invasive early cancer detection, they are not yet ready to replace tissue biopsies. Collectively, these advancements indicate a future where image-guided tissue sampling is more targeted, less invasive, and diagnostically accurate, although cost and technology access remain challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.